ConductScience.org, home

Paper37762008

Activation of G-Protein-Coupled Estrogen Receptor 1 (GPER1) Reduces Progression of Vulvar Carcinoma Cells.

Loris J and 4 others. Int J Mol Sci, 2023. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Activation of G-Protein-Coupled Estrogen Receptor 1 (GPER1) Reduces Progression of Vulvar Carcinoma Cells. Papers, record 37762008. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37762008

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Activation of G-Protein-Coupled Estrogen Receptor 1 (GPER1) Reduces Progression of Vulvar Carcinoma Cells.
PubMed
Journal
Int J Mol Sci
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.61
iCite
Revised in PubMed
2023-10-05
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Loris JJohanna
2Hanesch LLena
3Bauerschmitz GGerd
4Gallwas JJuliahttps://orcid.org/0000-0001-9640-1973
5Gründker CCarstenhttps://orcid.org/0000-0001-8828-7955

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CarcinomaMajor topic
Receptors, EstrogenMajor topic
Receptors, G-Protein-CoupledMajor topic
Vulvar NeoplasmsMajor topic
Female
Humans
Estrogen Receptor alpha
GTP-Binding Proteins

Source PubMed

Download CSV of topics

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129239277Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.J Int Med Res2018https://conductscience.org/library/papers/29239277PubMed
226175858G15 sensitizes epithelial breast cancer cells to doxorubicin by preventing epithelial-mesenchymal transition through inhibition of GPR30.Am J Transl Res2015https://conductscience.org/library/papers/26175858PubMed
333707570Four-decade trends in lymph node status of patients with vulvar squamous cell carcinoma in northern Italy.Sci Rep2021https://conductscience.org/library/papers/33707570PubMed
433117280Continuous Exposure of Breast Cancer Cells to Tamoxifen Upregulates GPER-1 and Increases Cell Proliferation.Front Endocrinol (Lausanne)2020https://conductscience.org/library/papers/33117280PubMed
523145207The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner.Am J Transl Res2012https://conductscience.org/library/papers/23145207PubMed
627107933The G protein-coupled estrogen receptor as a modulator of neoplastic transformation.Mol Cell Endocrinol2016https://conductscience.org/library/papers/27107933PubMed
731483053Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma.Histol Histopathol2020https://conductscience.org/library/papers/31483053PubMed
830227306Estrogen/GPR30 Signaling Contributes to the Malignant Potentials of ER-Negative Cervical Adenocarcinoma via Regulation of Claudin-1 Expression.Neoplasia2018https://conductscience.org/library/papers/30227306PubMed
924314615Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study.Lancet Oncol2014https://conductscience.org/library/papers/24314615PubMed
1024161432G15, a GPR30 antagonist, induces apoptosis and autophagy in human oral squamous carcinoma cells.Chem Biol Interact2013https://conductscience.org/library/papers/24161432PubMed
1120658519Crossing barriers: the new dimension of 2D cell migration assays.J Cell Physiol2011https://conductscience.org/library/papers/20658519PubMed
1211140706Validation of tissue microarray technology in breast carcinoma.Lab Invest2000https://conductscience.org/library/papers/11140706PubMed
1326433678Cancer of the vulva.Int J Gynaecol Obstet2015https://conductscience.org/library/papers/26433678PubMed
1421192171Clinical and pathologic features of vulvar intraepithelial neoplasia in premenopausal and postmenopausal women.J Low Genit Tract Dis2011https://conductscience.org/library/papers/21192171PubMed
1530727915GPER Overexpression in Cervical Cancer Versus Premalignant Lesions: Its Activation Induces Different Forms of Cell Death.Anticancer Agents Med Chem2019https://conductscience.org/library/papers/30727915PubMed
1621782022Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity.J Steroid Biochem Mol Biol2011https://conductscience.org/library/papers/21782022PubMed
1726527320Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs.Oncotarget2016https://conductscience.org/library/papers/26527320PubMed
1831611744Estrogen receptor subtype agonist activation in human cutaneous squamous cell carcinoma cells modulates expression of CD55 and Cyclin D1.EXCLI J2019https://conductscience.org/library/papers/31611744PubMed
198812536Epidemiologic data on vulvar cancer: comparison of hospital with population-based data.Gynecol Oncol1996https://conductscience.org/library/papers/8812536PubMed
2019591047Dose-dependent inhibition of BrdU detection in the cell proliferation ELISA by culture medium proteins.J Immunoassay Immunochem2009https://conductscience.org/library/papers/19591047PubMed

See all 40 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42379802Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells In Vitro.In Vivo2026https://conductscience.org/library/papers/42379802PubMed
41586754Overexpression of GPER1 suppressed esophageal carcinoma growth via activating cAMP pathway.Eur J Histochem2026https://conductscience.org/library/papers/41586754PubMed
40280717Expression of "Hallmarks of Cancer" Genes in Cervical Carcinoma Is Differentially Affected by GPER1 Overexpression Depending on Histologic Entity.Cancer Genomics Proteomics2025https://conductscience.org/library/papers/40280717PubMed
39730177G Protein-coupled Estrogen Receptor 1 (GPER1) Regulates Expression of SERPINE1/PAI-1 and Inhibits Tumorigenic Potential of Cervical Squamous Cell Carcinoma Cells In Vitro.Cancer Genomics Proteomics2025https://conductscience.org/library/papers/39730177PubMed
39467628Suppressing Expression of SERPINE1/PAI1 Through Activation of GPER1 Reduces Progression of Vulvar Carcinoma.Cancer Genomics Proteomics2024https://conductscience.org/library/papers/39467628PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37762008

GET https://conductscience.org/api/papers/v1/37762008/references?page=2